LEDDEGIGT – - Sundhedsstyrelsen

Litteratur
54 Rau R, Herborn G,
Menninger H, Sangha O.
Progression in early
erosive rheumatoid
arthritis: 12 month results
from a randomized
controlled trial
comparing methotrexate
and gold sodium
thiomalate. Br J
Rheumatol 1998;
37(11):1220-1226.
55 Menninger H, Herborn
G, Sander O,
Blechschmidt J, Rau R.
A 36 month comparative
trial of methotrexate
and gold sodium
thiomalate in the treatment
of early active
and erosive rheumatoid
arthritis. Br J Rheumatol
1998; 37(10):1060-1068.
56 Dixon AJ, Davies J,
Dormandy TL, Hamilton
EB, Holt PJ, Mason RM et
al.
Synthetic D(-) penicillamine
in rheumatoid
arthritis. Double-blind
controlled study of a
high and low dosage
regimen. Ann Rheum
Dis 1975; 34(5):416-421.
57 Eberhardt K, Rydgren L,
Fex E, Svensson B,
Wollheim FA.
D-penicillamine in early
rheumatoid arthritis:
experience from a 2-
year double blind
placebo controlled
study [see comments].
Clin Exp Rheumatol
1996; 14(6):625-631.
58 Golding JR, Andrews
FM, Camp V, Day AT,
Freeman AM, Golding
DN et al.
Controlled trial of penicillamine
in severe
rheumatoid arthritis.
Ann Rheum Dis 1973;
32(4):385-386.
59 Huskisson EC, Gibson TJ,
Balme HW, Berry H, Burry
HC, Grahame R et al.
Proceedings:
Penicillamine or gold
for rheumatoid arthritis?
Multicentre trial using
’blind’ observers.
The first six months.
Ann Rheum Dis 1974;
33(4):399.
60 Mery C, Delrieu F,
Ghozlan R, Saporta L,
Simon F, Amor B et al.
Controlled trial of D-
penicillamine in
rheumatoid arthritis.
Dose effect and the
role of zinc. Scand J
Rheumatol 1976;
5(4):241-247.
61 Shiokawa Y, Horiuchi Y,
Honma M, Kageyama T,
Okada T, Azuma T.
Clinical evaluation of
D-penicillamine by multicentric
double-blind
comparative study in
chronic rheumatoid
arthritis. Arthritis
Rheum 1977; 20(8):1464-
1472.
62 Suarez-Almazor ME,
Spooner C, Belseck E.
Penicillamine for treating
rheumatoid arthritis.
Cochrane Database
Syst Rev
2000;(4):CD001460.
63 Clark P, Casas E, Tugwell
P, Medina C, Gheno C,
Tenorio G et al.
Hydroxychloro-quine
compared with placebo
in rheumatoid arthritis.
A randomized controlled
trial [see comments].
Ann Intern Med
1993; 119(11):1067-1071.
64 Davis MJ, Dawes PT,
Fowler PD, Clarke S,
Fisher J, Shadforth MF.
Should disease-modifying
agents be used in
mild rheumatoid arthritis?
Br J Rheumatol 1991;
30(6):451-454.
65 Blackburn-WD J, Prupas
HM, Silverfield JC,
Poiley JE, Caldwell JR,
Collins RL et al.
Tenidap in rheumatoid
arthritis. A 24-week
double-blind comparison
with hydroxychloroquine-plus-piroxicam,
and piroxicam
alone [see comments].
Arthritis Rheum 1995;
38(10):1447-1456.
66 Suarez-Almazor ME,
Belseck E, Shea B,
Homik J, Wells G,
Tugwell P.
Antimalarials for treating
rheumatoid arthritis.
Cochrane Database
Syst Rev
2000;(4):CD000959.
67 Nuver Z, I, van Riel PL,
van de Putte LB,
Gribnau FW.
A double blind comparative
study of
sulphasalazine and hydroxychloroquine
in
rheumatoid arthritis:
evidence of an earlier
effect of sulphasalazine.
Ann Rheum Dis
1989; 48(5):389-395.
68 van der Heijde DM, van
Riel PL, Nuver Z, I,
Gribnau FW, vad-de-
Putte LB.
Effects of hydroxychloroquine
and sulphasalazine
on progression
of joint damage in
rheumatoid arthritis.
Lancet 1989;
1(8646):1036-1038.
69 Easterbrook M.
An ophthalmological
view on the efficacy
and safety of chloroquine
versus hydroxychloroquine.
J
Rheumatol 1999;
26(9):1866-1868.
70 Bernstein HN.
Ophthalmologic considerations
and testing
in patients receiving
long-term antimalarial
therapy. Am J Med 1983;
75(1A):25-34.
71 Houpt JB.
A rheumatologist’s verdict
on the safety of
chloroquine versus hydroxy-chloroquine.
Liability in off-label
prescribing. J
Rheumatol 1999;
26(9):1864-1866.
72 Urowitz MB, Gordon
DA, Smythe HA,
Pruzanski W, Ogryzio
MA.
Azathioprine in
rheumatoid arthritis. A
double-blind, cross over
study. Arthritis Rheum
1973; 16(3):411-418.
73 Levy J, Paulus HE,
Barnett EV, Sokoloff M,
Bangert R, Pearson CM.
A double-blind controlled
evaluation of
azathioprine treatment
in rheumatoid arthritis
and psoriatic arthritis.
Arthritis Rheum 1972;
15(1):116-117.
74 Woodland J, Chaput-de-
Saintonge DM, Evans SJ,
Sharman VL, Currey HL.
Azathio-prine in
rheumatoid arthritis:
double-blind study of
full versus half doses
versus placebo. Ann
Rheum Dis 1981;
40(4):355-359.
75 Suarez-Almazor ME,
Spooner C, Belseck E.
Azathioprine for treating
rheumatoid arthritis.
Cochrane Database
Syst Rev
2000;(4):CD001461.
76 Jeurissen ME,
Boerbooms AM, van de
Putte LB, Doesburg WH,
Lemmens AM.
Influence of methotrexate
and azathioprine on
radiologic progression
in rheumatoid arthritis.
A randomized, doubleblind
study. Ann Intern
Med 1991; 114(12):999-
1004.
77 Jeurissen ME,
Boerbooms AM, van de
Putte LB, Doesburg WH,
Mulder J, Rasker JJ et al.
Methotrexate versus
azathioprine in the
treatment of rheumatoid
arthritis. A fortyeight-week
randomized,
double-blind trial.
Arthritis Rheum 1991;
34(8):961-972.
78 Tugwell P, Bombardier
C, Gent M, Bennett KJ,
Bensen WG, Carette S
et al.
Low-dose cyclosporin
versus placebo in patients
with rheumatoid
arthritis. Lancet 1990;
335(8697):1051-1055.
79 Forre O.
Radiologic evidence of
disease modification in
rheumatoid arthritis patients
treated with cyclosporine.
Results of a
48-week multicenter
study comparing lowdose
cyclosporine with
placebo. Norwegian
Arthritis Study Group.
Arthritis Rheum 1994;
37(10):1506-1512.
80 Wells G, Haguenauer D,
Shea B, Suarez-Almazor
ME, Welch VA, Tugwell P.
Cyclosporine for rheumatoid
arthritis. Cochrane
Database Syst Rev
2000;(2):CD001083.
88 LEDDEGIGT – medicinsk teknologivurdering af diagnostik og behandling
LEDDEGIGT – medicinsk teknologivurdering af diagnostik og behandling 89